The news article says:
Antares Pharma had applied for approval of the product for men with physician-determined hypogonadism. The prefilled, single-use injector enables patients to self-administer testosterone at home instead of applying a patch or gel, or having an intramuscular injection in a doctor's office.
The FDA identified two safety concerns. First, that Xyosted could cause a clinically meaningful increase in blood pressure, and second, it is concerned about the occurrence of depression and suicidality.